1-16 of 16
Lillian L. Siu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Available to Purchase
Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (11): 1625–1631.
https://doi.org/10.1158/1535-7163.MCT-22-0655
Published: 03 November 2022
View articletitled, The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Open the PDF for The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission in another window
Journal Articles

Abstract LBA021: Immune resistance interrogation study (IRIS): Initial report of next generation sequencing (NGS) results in patients with primary versus acquired resistance to anti-PD1/L1 antibodies

Free
Sofia Genta, Farnoosh Abbas Aghababazadeh, Ming S Tsao, Aaron R Hansen, Marcus O Butler, Albiruni R Razak, Philippe L Bedard, Ben X Wang, Pugh J Trevor, Sevan Hakgor, Jeffrey Woo, Benjamin Haibe-Kains, Lillian L Siu, Anna Spreafico
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): LBA021.
https://doi.org/10.1158/1535-7163.TARG-21-LBA021
Published: 01 December 2021
View articletitled, Abstract LBA021: Immune resistance interrogation study (IRIS): Initial report of next generation sequencing (NGS) results in patients with primary versus acquired resistance to anti-PD1/L1 antibodies
Journal Articles

Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

Free
Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, Ivy S. Percy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P035.
https://doi.org/10.1158/1535-7163.TARG-21-P035
Published: 01 December 2021
View articletitled, Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)
Journal Articles

Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial

Free
Alberto Hernando-Calvo, Eoghan Malone, Daphne Dai, Amy Prawira, Ilan Weinreb, Anneli Eliason, Angela Rodriguez, Katherine Lajkosz, Sarah Jennings, Anna Spreafico, Lillian L. Siu, Aaron Hansen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P154.
https://doi.org/10.1158/1535-7163.TARG-21-P154
Published: 01 December 2021
View articletitled, Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial
Journal Articles

Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors

Free
Jeffrey Clarke, Siu-Chung Chu, Lillian L Siu, Jean-Pascal Machiels, Benjamin Markman, Kimberley Heinhuis, Michael Millward, Martijn Lolkema, Sandip Pravin Patel, Paul de Souza, Giuseppe Curigliano, Armando Santoro, Michelle Brown, Ronald Fleming, Heather Vezina, Chunsheng He, Sylvie Rottey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B057.
https://doi.org/10.1158/1535-7163.TARG-19-B057
Published: 01 December 2019
View articletitled, Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors
Journal Articles

Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.

Free
Miguel Quintela-Fandino, Monika Krzyzanowska, Gordon Duncan, Ashley Young, Malcolm J. Moore, Eric X. Chen, Anasthasios Stathis, Jennifer Petronis, Mandeep Grewal, Sheila Webster, Lisa Wang, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B23.
https://doi.org/10.1158/1535-7163.TARG-11-B23
Published: 12 November 2011
View articletitled, Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.
Journal Articles

Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Free
Lillian L. Siu, Ghassan Allo, Gregory R. Pond, Tong Zhang, James Ho, Sebastien J. Hotte, Scott A. Laurie, Simron Singh, Eric Winquist, Stephen K. L. Chia, Eric X. Chen, Kelvin K. Chan, Christine Mormont, Susan Quinn, Tao Wang, Ian Taylor, Suzanne Kamel-Reid, Ming S. Tsao, Denis Soulieres
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A50.
https://doi.org/10.1158/1535-7163.TARG-11-A50
Published: 12 November 2011
View articletitled, Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Journal Articles

Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).

Free
Vincent Castonguay, Philippe L. Bedard, Helen X. Chen, Percy Ivy, Amit M. Oza, Eric X. Chen, Hal W. Hirte, Angela McGarrity, Anne Laughlin, Sonya Lovell, Lisa Wang, Lillian L. Siu, Sebastien Hotte
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C17.
https://doi.org/10.1158/1535-7163.TARG-11-C17
Published: 12 November 2011
View articletitled, Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).
Journal Articles

Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Free
Albiruni RA Razak, Philippe L. Bedard, Benoit You, Devang Panchal, Eric X. Chen, S. Percy Ivy, Wen-Jiang Zhang, Suzanne Kamel-Reid, Nhu-An Pham, Tong Zhang, Sebastien J. Hotte, Michael Reedijk, Momiko Shimizu, Laurie Ailles, Christine Haines, Amit Oza, Ming Tsao, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B50.
https://doi.org/10.1158/1535-7163.TARG-11-B50
Published: 12 November 2011
View articletitled, Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
Journal Articles

Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).

Free
Suzanne Richter, Ben Tran, Krupa Patel, Alberto Ocana, Lisa Wang, Christine Haines, Melanie Recel, Eric X. Chen, Ian F. Tannock, Lillian L. Siu, Philippe L. Bedard
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C25.
https://doi.org/10.1158/1535-7163.TARG-11-C25
Published: 12 November 2011
View articletitled, Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).
Journal Articles

Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing.

Free
Ben Tran, Janet E. Dancey, Philippe L. Bedard, Suzanne Kamel-Reid, John D. McPherson, Lincoln D. Stein, Andrew MK Brown, Tong Zhang, Stuart Watt, Vincent Ferretti, Sangeet Ghai, Teresa Petrocelli, Patricia Shaw, Benjamin G. Neel, Nicole Onetto, Thomas J. Hudson, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B48.
https://doi.org/10.1158/1535-7163.TARG-11-B48
Published: 12 November 2011
View articletitled, Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing.
Journal Articles

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

Free
Miguel Quintela-Fandino, Christophe Le Tourneau, Ignacio Duran, Eric X. Chen, Lisa Wang, Ming Tsao, Bizhan Bandarchi-Chamkhaleh, Nhu-Ann Pham, Trevor Do, Martha MacLean, Rakesh Nayyar, Michael W. Tusche, Ur Metser, John J. Wright, Tak W. Mak, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (3): 751–760.
https://doi.org/10.1158/1535-7163.MCT-09-0868
Published: 09 March 2010
View articletitled, Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort
Open the PDF for Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort in another window
Journal Articles

Abstract B32: Retrospective correlative study between EGFRvIII, HPV, p16, c‐MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Free
Nicole G. Chau, Bayardo Perez‐Ordonez, Katherine Zhang, Nhu‐An Pham, James Ho, Tong Zhang, Lisa Wang, Ming‐Sound Tsao, Suzanne Kamel‐Reid, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B32.
https://doi.org/10.1158/1535-7163.TARG-09-B32
Published: 10 December 2009
View articletitled, Abstract B32: Retrospective correlative study between EGFRvIII, HPV, p16, c‐MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Journal Articles

Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Free
Lillian L. Siu, Sebastien J. Hotte, Eric X. Chen, Hal W. Hirte, Jean Powers, Lee‐Anne Stayner, Anne Iacobucci, Veronica Novotny‐Diermayr, Joy Zhu, Elizabeth A. Eisenhauer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A185.
https://doi.org/10.1158/1535-7163.TARG-09-A185
Published: 10 December 2009
View articletitled, Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors
Journal Articles

Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

Free
Lillian L. Siu, Kyriakos P. Papadopoulos, Steven R. Alberts, Sara Taylor, Amita Patnaik, Eric X. Chen, Anthony Tolcher, Blisse Vakkalaguada, Lixin Lang, Christoph Ahlers, Kelly L. Bennett, Jan M. Van Tornout
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A55.
https://doi.org/10.1158/1535-7163.TARG-09-A55
Published: 10 December 2009
View articletitled, Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors
Journal Articles

Raf kinase as a target for anticancer therapeutics

Free
Srikala S. Sridhar, David Hedley, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (4): 677–685.
https://doi.org/10.1158/1535-7163.MCT-04-0297
Published: 12 April 2005
View articletitled, Raf kinase as a target for anticancer therapeutics
Open the PDF for Raf kinase as a target for anticancer therapeutics in another window